Tomorrow.Bio raises €5M to ‘freeze’ people after death until revival becomes possible

Berlin-based Tomorrow.Bio, a cryonics company, has completed the first close of a €5M equity funding round.

The German company provides a service that preserves people in liquid nitrogen after death, with the intention of keeping them in that state until medical science develops a method to bring them back to life and restore their bodily functions.

Tomorrow.Bio’s seed investment round was co-led by French early-stage VC firm Blast.Club, and TruVenturo, the Family Office of Nils Regge. Additional funding came from angel investors, high-net-worth individuals, and existing investors.

Nils Regge, founder of Truventuro and investor in longevity, says, “Companies like Tomorrow.Bio are on the absolute forefront of visionary longevity approaches. We’re very happy to support these types of moonshots, that might not just have a big impact on the extension of life span but are also huge business opportunities.”

Anthony Bourbon, Founder and CEO of Blast.Club, adds, “Tomorrow.Bio’s cutting-edge technology is revolutionising the way we view life and death. The company has the necessary assets to overcome technological challenges and ensure sustainable growth. The ambitious yet realistic vision of the founders, Emil and Fernando, positions Tomorrow.Bio as what could be the future of medicine.”

Capital utilisation

The funds will help the German company to expand into the United States, starting with locations in New York, California, and Florida. It will increase investment in research and development to enhance its preservation methods.

Dr. Emil Kendziorra, Founder and CEO of Tomorrow.Bio, says, “We’re extremely happy to have found visionary investors to continue our long-term mission. Not only by expanding our coverage to the US but also by doubling down on R&D to further improve preservation quality and stay far ahead of all competition.”

Enabling lifespan choice

Founded in 2020 by Dr. Emil Kendziorra and Fernando Azevedo Pinheiro, Tomorrow.Bio offers cryopreservation services for humans and animals.

The company has cryopreserved 20 individuals and 10 pets, with over 800 more registered. Its total contract value has exceeded €160M.

Cryopreservation involves cooling the body to minus 196°C to stop biological processes. Tomorrow.Bio uses cryo-ambulances to retrieve individuals after legal death and begin the cooling process during transport to a facility in Switzerland.

The company’s “standby teams” currently operate from Berlin and Zurich, with more locations planned in Europe and the US. These teams perform chest compressions, supply oxygen, and initiate the cooling process following legal pronouncement of death.

Tomorrow.Bio also replaces body fluids with a cryoprotectant solution to prevent ice crystal formation during cooling. 

As part of its expansion into the US, the company plans to establish partner medical teams in at least three new locations. This move positions Tomorrow.Bio to become the first company to offer local teams that can begin the cryopreservation process immediately after legal death.

Tomorrow.Bio works with its sister organisation, the European Biostasis Foundation, based in Rafz, Switzerland. This is where cryopreserved individuals are stored. 

The facility uses vacuum-insulated steel containers, called dewars, each 3.2 meters tall. These containers are filled with liquid nitrogen and operate without electricity to maintain low temperatures.